Recce Pharmaceuticals Ltd. · ASX:RCE

Recce Pharmaceuticals — Investor Presentation (November 2026)

45 slides from Recce Pharmaceuticals's investor presentation, November 2026

  1. Slide 1: RCE Corporate Presentation

    Slide 1: RCE Corporate Presentation

    RCE Corporate Presentation ASX:RCE | FSE:R9Q November 2026 0

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer DISCLAIMER FUTURE MATTERS This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of not purport to contain all the information that a prospecti

  3. Slide 3: Company Overview

    Slide 3: Company Overview

    Company Overview

  4. Slide 4: Recce Pharmaceuticals – Company Overview

    Slide 4: Recce Pharmaceuticals – Company Overview

    Recce Pharmaceuticals – Company Overview Recce Pharmaceuticals is a leading, Australian anti-infective company approaching near term commercialisation milestones Products address the global healthcare crisis of antibiotic resistance: working faster than traditional antibiotics and against multidrug

  5. Slide 5: Board and Management Structure

    Slide 5: Board and Management Structure

    Board and Management Structure Dr John Prendergast – Chairman BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU) Michele Dilizia – Executive Director & Chief Scientific Officer BSc (Med Sc i), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM US-based, current Chairman and Co-founder of Palatin Technologies,

  6. Slide 6: Capital Structure and Share Price

    Slide 6: Capital Structure and Share Price

    Capital Structure and Share Price Recce Pharmaceuticals Ltd is a clinical-stage biotech company with a new class of novel synthetic anti-infectives Capital Structure – November 2026 RCE Share Price and Volume Chart – 12 Months (price shown in AUD) ASX & FSE Code RCE, R9Q 12,000,000 $0.80 Share Price

  7. Slide 7: The Advantages of a New Class of Antibiotics

    Slide 7: The Advantages of a New Class of Antibiotics

    The Advantages of a New Class of Antibiotics Recce is on-track to be the only global clinical stage company whose drug is shown to be efficacious against the full suite of ESKAPE pathogens Unprecedented, broad-spectrum activity against Gram-positive and Gram-negative bacteria Universal Mechanism of

  8. Slide 8: Large Addressable Market US$5.8B

    Slide 8: Large Addressable Market US$5.8B

    Large Addressable Market The global diabetic foot infection (DFI) market represents a substantial burden on global healthcare systems INDONESIA MENA GLOBAL US$5.8B >20 million adults in Indonesia with >84 million adults in MENA region >589 million adults globally with Est. global DFI diabetes3 with

  9. Slide 9: Company Pipeline driven by 1st approval in Diabetic Foot Infections

    Slide 9: Company Pipeline driven by 1st approval in Diabetic Foot Infections

    Company Pipeline driven by 1st approval in Diabetic Foot Infections 2026 2027 Core Programs 155-patient R327G R327G Registrational Phase 3 trial recruitment interim analysis registrable registrable and dosing continue uninterrupted and readout in Indonesia in ASEAN R327G Topical Diabetic foot infect

  10. Slide 10: Commercial & Licensing

    Slide 10: Commercial & Licensing

    Commercial & Licensing 9

  11. Slide 11: Australia and New Zealand Licence Agreement

    Slide 11: Australia and New Zealand Licence Agreement

    Australia and New Zealand Licence Agreement Recce has signed a binding exclusive licence agreement with Arrotex Pharmaceuticals to commercialise R327G A direct commercial route for R327G in Australia and New Zealand Agreement Highlights Partnership with Arrotex Pharmaceuticals Commercial Costs Cover

  12. Slide 12: Middle Eastern Pharmaceutical Company Term Sheet

    Slide 12: Middle Eastern Pharmaceutical Company Term Sheet

    Middle Eastern Pharmaceutical Company Term Sheet Recce has signed a non-binding term sheet with a leading Middle Eastern Pharmaceutical Company for a 10-year exclusive multi-country licensing agreement for the licensing of R327G through the MENA region Term Sheet Highlights • The MENA region has a d

  13. Slide 13: RECCE 327 Synthetic Anti-Infective

    Slide 13: RECCE 327 Synthetic Anti-Infective

    RECCE® 327 Synthetic Anti-Infective 12

  14. Slide 14: Independent Study Undertaken on RECCE 327 MoA

    Slide 14: Independent Study Undertaken on RECCE 327 MoA

    Independent Study Undertaken on RECCE® 327 MoA1 Linnaeus Biosciences MoA studies of R327 Novel mechanism which targets rapid access to and shut down of bacterial energy production (ATP), which results in bacterial death of both active and resting bacteria. Stage 2 Stage 4 Stage 1 Stage 3 R327 target

  15. Slide 15: RECCE 327 Maintains Activity

    Slide 15: RECCE 327 Maintains Activity

    RECCE® 327 Maintains Activity Amoxicillin loses activity after a maximum of 8 repeats; RECCE ® 327 remains active for more than 25 repeats 25 repeats at time of discovery was sufficient for PCT patent applications, with no sign of resistance. Number of repeats before displaying loss of antibiotic ac

  16. Slide 16: Bactericidal Effect of RECCE 327 on ESKAPE Pathogens

    Slide 16: Bactericidal Effect of RECCE 327 on ESKAPE Pathogens

    Bactericidal Effect of RECCE® 327 on ESKAPE Pathogens E. faecium ATCC 19434 S. aureus ATCC 29213 K. pneumoniae ATCC 43816 A. baumannii ATCC 17978 P. aeruginosa ATCC 27853 Enterobacter cloacae ATCC 13047 • Average time-kill curves of R327 at various concentrations against strains of ESKAPE pathogens

  17. Slide 17: RECCE 327 Topical Gel

    Slide 17: RECCE 327 Topical Gel

    RECCE® 327 Topical Gel 16

  18. Slide 18: RECCE Topical Gel

    Slide 18: RECCE Topical Gel

    RECCE® 327 Topical Gel First-Line Local Treatment for Infected Wounds No Pathogen Identification Required Rapid Clinical Response • Applied directly to infected tissue • Clinical and TGA Special Access Scheme use demonstrates visible reduction in • Localised antimicrobial action at the site of infec

  19. Slide 19: DFIs: Addressing a High-Burden Infection Setting

    Slide 19: DFIs: Addressing a High-Burden Infection Setting

    DFIs: Addressing a High-Burden Infection Setting DFIs are complex infection Local infection RECCE® 327G was designed environments management in DFIs with DFI complexity in mind • Compromised blood flow, impaired • Direct delivery of anti-infective • Designed for direct application immune response an

  20. Slide 20: Dual Phase 3 Clinical Trial Strategy

    Slide 20: Dual Phase 3 Clinical Trial Strategy

    Dual Phase 3 Clinical Trial Strategy Two Phase 3 Clinical Trials, in Australia and Indonesia Indonesia Phase 3 Australia Phase 3 Registrational, multi-centre, double-blind, placebo-controlled Conducted to TGA and US FDA regulatory standards, Active- comparator design: R327G versus one of four physic

  21. Slide 21: Regulatory Acceleration & ASEAN Commercial Entry

    Slide 21: Regulatory Acceleration & ASEAN Commercial Entry

    Regulatory Acceleration & ASEAN Commercial Entry High-Impact • ~20M people living with diabetes Market • In Indonesia, DFIs are severe in 67.1% of hospitalised cases and result in amputation in 46.9% of patients1. • In-hospital treatment costs averaging IDR 64.95 million (USD ~$4,100) per patient1.

  22. Slide 22: Registrational Phase 3 Clinical Trial - Indonesia

    Slide 22: Registrational Phase 3 Clinical Trial - Indonesia

    Registrational Phase 3 Clinical Trial - Indonesia Study Title: Phase 3, Double-blind, Placebo-Controlled Study of R327 Topical Gel for the Treatment of Diabetic Foot Ulcer Infections Population Up to 310 participants will Intervention be enrolled who present with a mild diabetic foot infection. Part

  23. Slide 23: Indonesia Phase 3: Independent DMC Review Underway

    Slide 23: Indonesia Phase 3: Independent DMC Review Underway

    Indonesia Phase 3: Independent DMC Review Underway Blinded Data across 75 patients has shown • Review of the blinded data indicates strong efficacy across the study population 75 90 • RECCE® 327 Gel (R327G) continues to demonstrate Patients submitted for Patients currently enrolled an excellent safe

  24. Slide 24: Phase 3 DFI Clinical Trial Expands in Australia

    Slide 24: Phase 3 DFI Clinical Trial Expands in Australia

    Phase 3 DFI Clinical Trial Expands in Australia HREC approves protocol amendment adding randomised, active-controlled, non-inferiority component ~80% HREC approval significantly expands DFI Total Mild + Moderate patient pool from Mild to Mild + Moderate 47% Mild DFI Was Now Ulcer Below ankle Below k

  25. Slide 25: Phase 3 DFI Clinical Trial in Australia

    Slide 25: Phase 3 DFI Clinical Trial in Australia

    Phase 3 DFI Clinical Trial in Australia HREC approves protocol amendment adding randomised, active-controlled, non-inferiority + superiority component Protocol amendment adds moderate DFI. Mild and Moderate DFI together represent 80% of DFI presentations.  Head-to-head comparison against existing a

  26. Slide 26: Topical Clinical Programs – Previously Completed

    Slide 26: Topical Clinical Programs – Previously Completed

    Topical Clinical Programs – Previously Completed • Interim data results released – primary endpoints achieved Phase I/II • Patients supported by in-home (out-patient) nurses trained in Clinical Trial R327 treatment protocols Diabetic Foot • Study across South Western Sydney health district – one of

  27. Slide 27: Phase II ABSSSI Clinical Trial Achieved all Endpoints

    Slide 27: Phase II ABSSSI Clinical Trial Achieved all Endpoints

    Phase II ABSSSI Clinical Trial Achieved all Endpoints Study: Phase II study as an open-label clinical trial evaluating the safety and tolerability, efficacy, and plasma pharmacokinetics of R327G when applied directly to the infected area NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNI

  28. Slide 28: Patient Case Study – TGA Special Access Scheme Category A

    Slide 28: Patient Case Study – TGA Special Access Scheme Category A

    Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 0 Day 1 Day 30 Day 0 – Recce treatment Day 0 – Recce treatment Day 1 – Recce treatment Day 30 – Recce treatment Pre-treatment infection First Recce gel applied Post treatment Post treatment • Patient A unresponsive to 4x daily Cepha

  29. Slide 29: Patient Case Study – TGA Special Access Scheme Category A

    Slide 29: Patient Case Study – TGA Special Access Scheme Category A

    Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 7 Day 14 Day 10 Day 0 – Recce treatment Day 7 – Recce treatment Day 10 – Recce treatment Day 14 – Recce treatment Significant bacterial infection Wound drying up Post treatment Wound improved, well tolerated • Pre-treatment of R327G

  30. Slide 30: Patient Case Study – TGA Special Access Scheme Category A

    Slide 30: Patient Case Study – TGA Special Access Scheme Category A

    Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 7 Day 14 Day 21 Day 0 – Pre-treatment wound swab Day 7 – Recce treatment Day 14 – Recce treatment Day 21 – Recce treatment • Pre-treatment wound swab on Day 0 showed a growing culture ✓ Day 21 post-treatment, the wound had of both G

  31. Slide 31: Patient Case Study – TGA Special Access Scheme Category A

    Slide 31: Patient Case Study – TGA Special Access Scheme Category A

    Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 3 Day 7 Significant bacterial infection Redness and swelling Day 0 – Pre-treatment Day 3 – Recce treatment Day 7 – Recce treatment • Pre-treatment of R327G showed significant bacterial infection, ✓ Day 7 post-treatment showed wound

  32. Slide 32: Patient Case Study – TGA Special Access Scheme Category A

    Slide 32: Patient Case Study – TGA Special Access Scheme Category A

    Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 3 Day 7 Day 0 – Pre-treatment Day 3 – Recce treatment Day 7 – Recce treatment • Pre-treatment (Day 0) X-rays showed infection deep within the ✓ Day 7 post R327G treatment showed wound underlying bone, tissue and around the nail, wit

  33. Slide 33: Patient Case Study – TGA Special Access Scheme Category A

    Slide 33: Patient Case Study – TGA Special Access Scheme Category A

    Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 5 Significant bacterial infection Day 0 – Pre-treatment Day 5 – Recce treatment • Significant bacterial infection – septic ankle arthritis, peri- ✓ The discharge has cleared, and with no signs Left femoral prosthetic joint infection

  34. Slide 34: RECCE 327 Clinical Programs

    Slide 34: RECCE 327 Clinical Programs

    RECCE® 327 Clinical Programs 37

  35. Slide 35: R327 Faster Acting Than Existing Antibiotics

    Slide 35: R327 Faster Acting Than Existing Antibiotics

    R327 Faster Acting Than Existing Antibiotics No Prolonged Exposure Needed R327 is faster-acting against bacteria than other antibiotics – works quickly, without prolonged cellular exposure times required of other antibiotics (extended exposures commonly associated with systemic toxicity). R327 desig

  36. Slide 36: RECCE 327 Summary Results – Phase I – Complete

    Slide 36: RECCE 327 Summary Results – Phase I – Complete

    RECCE® 327 Summary Results – Phase I – Complete Double-blind, Placebo-controlled, Single Ascending-dose, Safety and Pharmacokinetic Study in Healthy Participants ✓ Safe and well tolerated at doses up to 6,000mg given as a 1-hour intravenous infusion; ✓ No Serious Adverse Events; – All AE’s mild or m

  37. Slide 37: RECCE Concentrates Safely in the Urine

    Slide 37: RECCE Concentrates Safely in the Urine

    RECCE® 327 Concentrates Safely in the Urine Concentration of R327 Ratio Urine/Plasma in Urine Compared to Plasma 16x 17x 14x 9x In over 60 21x healthy subjects 16x – R327 primary route of elimination appears to be through – Opportunities for therapeutic in array of UTIs (uncomplicated the kidney to

  38. Slide 38: RECCE Kills Quickly in the Urine

    Slide 38: RECCE Kills Quickly in the Urine

    RECCE® 327 Kills Quickly in the Urine E. coli ATCC 25922 Treated with RECCE® 327 in Urine • R327 in the presence of human urine was able to have 10.00 a fast (near minutes) effect against E. coli and irreversible 9.00 Viable Bacteria (log CFU/ml) • Bacteria could not be revived post-treatment 8.00 •

  39. Slide 39: Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial

    Slide 39: Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial

    Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial UTIs are responsible for about 30% of all sepsis infections, defined as ‘Urosepsis’ Clinical Trial Complete R327 has achieved multiple ‘fast infusion’ time stamps in line with intended future Assessment Assessing R327 at faster administration ra

  40. Slide 40: Intellectual Property & Manufacturing

    Slide 40: Intellectual Property & Manufacturing

    Intellectual Property & Manufacturing 43

  41. Slide 41: Robust Worldwide Intellectual Property Portfolio

    Slide 41: Robust Worldwide Intellectual Property Portfolio

    Robust Worldwide Intellectual Property Portfolio Recce’s patent portfolio contains over 40 patents and patent applications in the world’s major markets. Patent Patent Patent Patent Filed Expiry Expiry Expiry Expiry Family 1 Family 2 Family 3 Family 4 Australia ✓ 2028 ✓ 2037 ✓ 2037 ✓ 2041 Family 1 gr

  42. Slide 42: Manufacturing & Scalability

    Slide 42: Manufacturing & Scalability

    Manufacturing & Scalability Manufacturing facility in Sydney’s Macquarie Park Raw materials No expensive waste Automated manufacture process Plentiful and cheap – few 99.9% product yield Completing 5,000 doses a $/Kg week under GMP Clear benefits in cost GMP Manufacturing Capability to and scalabili

  43. Slide 43: RECCE 327 – Global Recognition

    Slide 43: RECCE 327 – Global Recognition

    RECCE® 327 – Global Recognition R327 added to World Health Organization’s List of Antibacterial Products in Clinical Development • Global recognition by the World Health Organization (WHO) – inclusion underscores significance of R327 in combating antimicrobial resistance. • Unique Mechanism of Actio

  44. Slide 44: Progress with the U.S. Department of War

    Slide 44: Progress with the U.S. Department of War

    Progress with the U.S. Department of War Collaboration with the U.S. Department of War in advancing next-generation of anti-infectives U.S. Army Medical CDMRP Grant US$2 million 1st CRADA Research Institute of 2nd CRADA – Feb 2026 Infectious Diseases (USAMRIID) Congressionally Directed Medical Coope

  45. Slide 45: Thank you

    Slide 45: Thank you

    Thank you @0@ recce.com.au

Source: company website

More decks from Recce Pharmaceuticals Ltd.

All 45 Recce Pharmaceuticals decks